Work

Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan ― An Interrupted Time Series Analysis ―

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors and loop diuretics have beneficial diuretic effects in patients with heart failure but may increase the risk of excessive water loss. Therefore, clinical guidelines recommend adjustment of loop diuretic doses when these agents are used concomitantly. However, real-world evidence regarding changes in loop diuretic dosing is limited. This study evaluated changes in prescribed doses of oral loop diuretics in patients with heart failure receiving dapagliflozin or empagliflozin before and after publication of the JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Methods and Results: Changes in prescribed dose trends were evaluated using monthly aggregated prescription data obtained from the Medical Data Vision database (Medical Data Vision, Inc., Tokyo, Japan). After publication of the guideline, statistically significant decreases were observed in the empagliflozin-prescribed group for azosemide (-0.1756 mg/month; P=0.0360), furosemide (-0.2180 mg/month; P=0.0485), and torsemide (-0.0387 mg/month; P=0.0378), and in the dapagliflozin-prescribed group for azosemide (-0.8221 mg/month; P=0.0260). The study period for dapagliflozin was too short to provide adequate statistical power. Conclusions: The publication of the JCS/JHFS 2021 guideline was associated with decreases in prescribed doses of oral loop diuretics. Dose reduction of oral loop diuretics may be considered in patients receiving concomitant SGLT2 inhibitors in clinical practice.
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7212116348
FWCI:
Cites: 32
Cited by:
Related to: 10